Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO1998049321) ADENOVIRUS-MEDIATED INTRATUMORAL DELIVERY OF AN ANGIOGENESIS ANTAGONIST FOR THE TREATMENT OF TUMORS
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/1998/049321 International Application No.: PCT/EP1998/002491
Publication Date: 05.11.1998 International Filing Date: 27.04.1998
Chapter 2 Demand Filed: 09.11.1998
IPC:
A61K 38/48 (2006.01) ,A61K 38/49 (2006.01) ,A61K 48/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
43
Enzymes; Proenzymes; Derivatives thereof
46
Hydrolases (3)
48
acting on peptide bonds (3.4)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
43
Enzymes; Proenzymes; Derivatives thereof
46
Hydrolases (3)
48
acting on peptide bonds (3.4)
49
Urokinase; Tissue plasminogen activator
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48
Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Applicants:
RHONE-POULENC RORER S.A. [FR/FR]; 20, avenue Raymond Aron F-92160 Antony, FR (AL, AM, AT, AU, AZ, BA, BB, BE, BF, BG, BJ, BR, BY, CA, CF, CG, CH, CI, CM, CN, CU, CY, CZ, DE, DK, EE, ES, FI, FR, GA, GB, GE, GH, GM, GN, GR, GW, HU, ID, IE, IL, IS, IT, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MC, MD, MG, MK, ML, MN, MR, MW, MX, NE, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, SN, SZ, TD, TG, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW)
LI, Hong [CN/FR]; FR (UsOnly)
LU, He [CN/FR]; FR (UsOnly)
GRISCELLI, Frank [FR/FR]; FR (UsOnly)
OPOLON, Paule [FR/FR]; FR (UsOnly)
SORIA, Claudine [FR/FR]; FR (UsOnly)
RAGOT, Thierry [FR/FR]; FR (UsOnly)
LEGRAND, Yves [FR/FR]; FR (UsOnly)
SORIA, Jeannette [FR/FR]; FR (UsOnly)
MABILAT, Christelle [FR/FR]; FR (UsOnly)
PERRICAUDET, Michel [FR/FR]; FR (UsOnly)
YEH, Patrice [FR/FR]; FR (UsOnly)
Inventors:
LI, Hong; FR
LU, He; FR
GRISCELLI, Frank; FR
OPOLON, Paule; FR
SORIA, Claudine; FR
RAGOT, Thierry; FR
LEGRAND, Yves; FR
SORIA, Jeannette; FR
MABILAT, Christelle; FR
PERRICAUDET, Michel; FR
YEH, Patrice; FR
Agent:
DERNONCOUR, Roxane; Rhone-Poulenc Rorer S.A. Direction Brevets 20, avenue Raymond Aron F-92165 Antony Cedex, FR
Priority Data:
60/044,98028.04.1997US
Title (EN) ADENOVIRUS-MEDIATED INTRATUMORAL DELIVERY OF AN ANGIOGENESIS ANTAGONIST FOR THE TREATMENT OF TUMORS
(FR) APPORT INTRATUMORAL, INDUIT PAR UN ADENOVIRUS, D'UN ANTAGONISTE D'ANGIOGENESE DESTINE AU TRAITEMENT DE TUMEURS
Abstract:
(EN) The present invention relates to gene therapy for the treatment of tumors. The invention more particularly relates to introduction of a gene encoding an anti-angiogenic factor into cells of a tumor, for example with a defective adenovirus vector, to inhibit growth or metastasis, or both, of the tumor. In a specific embodiment, delivery of a defective adenovirus that expresses the amino terminal fragment of urokinase (ATF) inhibited growth and metastasis of tumors. These effects were correlated with a remarkable inhibition of neovascularization within, and at the immediate vicinity of, the injection site. Delivery of a defective adenovirus vector that expresses kringles 1 to 3 of angiostatin inhibited tumor growth and tumorigenicity, and induced apoptosis of tumor cells. The invention further provides viral vectors for use in the methods of the invention.
(FR) La présente invention concerne l'utilisation de thérapie génique dans le traitement de tumeurs et notamment l'introduction d'un gène codant un facteur antiangiogénique dans des cellules d'une tumeur, par exemple, au moyen d'un vecteur adénoviral défectif, afin d'inhiber la croissance ou la métastase, ou les deux, de la tumeur. Dans un mode de réalisation spécifique, l'apport d'un adénovirus défectif exprimant le fragment aminé terminal de l'urokinase (ATF) a inhibé la croissance et la métastase de tumeurs. Ces effets sont en corrélation avec une inhibition remarquable de la néoformation de vaisseaux sanguins dans le site d'injection et au voisinage immédiat de celui-ci. L'apport d'un vecteur adénoviral défectif exprimant les kringles 1 à 3 de l'angiostatine a inhibé la croissance tumorale et l'action tumorigène et induit l'apoptose de cellules tumorales. L'invention concerne en outre des vecteurs viraux, utiles dans les procédés ci-dessus.
Designated States: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU
African Regional Intellectual Property Organization (ARIPO) (GH, GM, KE, LS, MW, SD, SZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
CZPV1999-3772NO19995242MXPA/a/1999/009594KR1020010020342IL132323EP0979290
US6638502JP2001523103 CN1254378CA2288306AU1998079096